Previous studies have demonstrated that breast cancers with these mutations are sensitive to (some) kinase inhibitors but not to monoclonal antibody-based therapies, and indeed often lack an external HER2 membrane domain31,32. This evidence concerns the gene ERBB2 and breast carcinoma.